ArticleAnnals of thoracic surgery short reports2026
The Impact of Preexisting Diabetes Mellitus on Chronic Lung Allograft Dysfunction After Lung Transplantation.
Article in Annals of thoracic surgery short reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Early safety observations of peri-transplant SGLT2 inhibitor use in lung transplant recipients.Journal of thoracic disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chronic lung allograft dysfunction (CLAD) remains a major cause of mortality after lung transplantation. Diabetes mellitus (DM) may contribute to CLAD through metabolic dysregulation. We evaluated post-lung transplant outcomes in recipients with DM. Methods: Adults undergoing first-time, isolated lung transplant (November 2017 to December 2024) with at least 6 months of follow-up were identified in the United Network for Organ Sharing registry and stratified by DM diagnosis at waitlist registration. CLAD was defined as ≥20% forced expiratory volume in 1 second and/or forced vital capacity decline after >3 months follow-up. Kaplan-Meier and multivariable Cox models assessed survival and CLAD risk, with subgroup analysis by race and ethnicity. Results: Among 18,199 analyzed patients, 3479 (18.3%) had DM. CLAD rates were higher among recipients with DM (21.3% vs 17.4%, Conclusions: Recipient DM is associated with reduced long-term survival and CLAD risk after lung transplant. Asian American recipients with DM appear to face disproportionately worse survival, suggesting a potential interaction between race, ethnicity, and metabolic status.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.